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Summary – Abstract (200 words)  43 
 44 
Objective: Cognitive impairments (CI) have recently been identified in canine epilepsy 45 
patients. A medium-chain triglyceride (MCT) enriched diet has been demonstrated to improve 46 
cognition in aged dogs and seizure control in canine epilepsy. This study evaluates the short-47 
term effects of MCT oil consumption on cognitive abilities in dogs with epilepsy, a naturally 48 
occurring animal model. 49 
 50 
Methods: A 6-month multi-center, prospective, randomized, double-blinded, controlled cross-51 
over diet trial was conducted comparing dietary supplementation (DS) of MCT-oil to a control 52 
oil. Allocation to dietary oil supplements, consisting of 9% total caloric intake, was block-53 
randomized and supplemented into each dogs’ diet for three months followed by a respective 54 
switch of DS oil for a further three months. Non-invasive cognitive tests and a validated 55 
psychometric tool were utilized to evaluate cognitive function and perturbations associated 56 
with dietary intervention. 57 
 58 
Results: Twenty-nine dogs completed the trial, of which 18 completed non-invasive cognitive 59 
testing. Spatial-working memory (p=0.008), problem-solving ability (p=0.048) and owner-60 
reported trainability (p=0.041) were significantly improved during MCT-oil supplementation 61 
compared to control-DS.  62 
 63 
Significance: MCT-oil DS improves cognition in dogs with epilepsy when compared to a 64 
control-DS. MCT supplementation may represent a promising option to address CI associated 65 






The relationship between cognitive impairment (CI) and epilepsy has been extensively studied 70 
in people[1]. During the course of epilepsy, the occurrence of impaired cognitive function is 71 
very common. The enduring predisposition to epileptic seizures can trigger or exacerbate 72 
underlying CI in those patients. Approximately every second newly diagnosed child or adult 73 
with epilepsy has detectable cognitive or behavioural abnormalities. The degree of cognitive 74 
compromises (affecting learning ability, memory and attention), is diverse and depends on 75 
contributing factors such as seizure control, seizure type, age of onset and pharmacotherapy[1].  76 
 77 
Canine epilepsy, a naturally occurring animal model, is associated with a higher risk of 78 
premature death, behavioural comorbidities[2, 3] and recently recognised cognitive deficits [4, 79 
5]. Compared to healthy controls, dogs with epilepsy demonstrate dementia-like CI at a 80 
younger age[5], reduced trainability under polytherapy or specific anti-seizure drug (ASD) 81 
treatment[4] and exhibit impairments in their spatial-working memory[6]. Thus, the 82 
development of new or alternative treatment options that address CI as well as seizure control 83 
should be prioritised. 84 
 85 
Diet has been shown to influence signs of age or disease related CI in both humans and dogs. 86 
One method of dietary intervention to improve CI is aimed at counteracting the undesirable 87 
age-associated reduction in cerebral glucose metabolism by providing alternative metabolites 88 
such as ketone bodies[7]. In epilepsy, it is hypothesized that the chronic condition of inefficient 89 
glycolysis can also initiate and promote epileptogenesis[7, 8]. Dietary intervention may 90 
therefore be simultaneously beneficial for CI and epilepsy[9]. Medium-chain triglycerides 91 
(MCT) are proposed to counter impaired utilization of glucose via increased ketone production 92 
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as one downstream metabolite[7], and are also reported to evoke anticonvulsant properties 93 
themselves[10].  Most recently, an MCT-enriched diet was shown to improve seizure 94 
control[11, 12] and anxiety[2] in dogs with epilepsy, but also cognition in aged dogs [13]. In 95 
veterinary medicine, two-third of patients continue to have seizures on ASDs with one-third of 96 
dogs continue to suffer from inadequate seizure control despite appropriately managed 97 
polypharmacotherapy. Veterinarians have a limited number of ASDs to choose from, often 98 
associated with adverse-effects that reduce quality of life, thus elevating the importance of non-99 
drug therapies.  100 
 101 
In human medicine, only one clinical study has assessed cognitive abilities in children and 102 
adolescents with epilepsy treated with a ketogenic diet (KD). In 2016, Ijff and colleagues 103 
reported a positive impact on cognitive functioning in children and adolescents after four 104 
months of KD consumption. An improved mood and cognitive activation with increased 105 
productivity were observed. 71% of the cases reported used an MCT based KD [14]. 106 
 107 
Consequently, MCTs are a promising dietary component to simultaneously address comorbid 108 
CI and a new management strategy for insufficient seizure control in dogs and humans with 109 
epilepsy. 110 
 111 
The aim of this study was to investigate whether MCTs, when given as a daily dietary 112 







Methods  118 
 119 
Study Design and recruitment 120 
Cognitive abilities were assessed as part of a 6-month prospective, randomised, double-121 
blinded, controlled, multicentre dietary crossover trial comparing an MCT-DS to a 122 
standardised control oil DS for the management of canine epilepsy. The clinical trial study 123 
design protocol has previously been reported in detail and the study results for seizure control 124 
showed an overall significant reduction in the MCT-DS phase of the study[12, 15]. Briefly, 125 
dogs diagnosed with idiopathic epilepsy (International Veterinary Epilepsy Task Force tier II 126 
level diagnosis) and not responding  with 50% seizure frequency reduction to at least one 127 
appropriately chosen and administered ASD were recruited. Dogs were block randomised and 128 
assigned a DS-1, either the MCT- or control-DS, alongside their normal diet and fed initially 129 
for three months (day 1 to day 90 ± 2), followed by a 7-day washout phase and switch to the 130 
alternative DS-2 for another three months (day 90 to day 187 ± 2). Concomitant changes of 131 
ASD medication or diet during the study resulted in exclusion.  132 
 133 
Assessment methods for cognitive abilities  134 
Depending on the study centre’s facilities, two cognitive tasks and a psychometric tool were 135 
conducted to assess cognitive function during each DS phase:  136 
 137 
Cognitive performance tasks (N =18):   138 
Dogs underwent two validated, non-invasive tests to measure different aspects of cognition 139 
(task 1: spatial-working memory, task 2: problem-solving [6, 16]). The cognitive assessments 140 
were performed in an empty standardized examination room with reduced sensory distractions. 141 
Dogs were live scored during the tasks (Figure 1). Each dog received an overall mean 142 
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performance score for four consecutive repeats for each of the two tasks. The percentage 143 
change relative to baseline scores (positive = improvement, negative = deterioration) for MCT 144 
and control-DS were compared. Not every facility had the set-up to perform the cognitive tests 145 
and thus data are not available for all dogs.  146 
 147 
Canine Cognitive Dysfunction Rating scale (CCDR) (N = 29): 148 
The CCDR rating system is a psychometrically validated and well-established veterinary 149 
questionnaire tool to quantify signs of canine dementia [17]. Questions on thirteen behavioral 150 
traits are used to calculate the overall CCDR score out of 80 for each dog (0-39 = normal; 40-151 
49 = at risk; >50 = CCD).  Individual scores were subsequently compared between both study 152 
phases normalized to baseline. As level of canine training, age and number of ASD may 153 
influence signs of CI, these effects were taken into account in statistical analyses and reported, 154 
where relevant. 155 
 156 
Canine Behavioral Assessment & Research Questionnaire (C-BARQ) (N = 29): 157 
Trainability was evaluated with the C-BARQ[18] which was designed to provide standardized 158 
evaluations of canine behavior. The trainability subscale consists of eight items, the scores of 159 
which are averaged to derive an overall change in trainability score relative to baseline. This 160 
overall score was compared between both dietary periods. 161 
 162 
Ketone Body Measurements 163 
Pre- and post-prandial beta-hydroxybutyrate (BHB) concentrations were analyzed on each visit 164 
day (V1-V3). Pre-prandial blood samples were collected in the morning after fasting for at least 165 
12h, while post-prandial samples were taken two hours after consumption of their usual diet 166 
with the prescribed amount of DS. Collected serum was then shipped for subsequent analysis 167 
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to two local laboratories. 168 
 169 
Statistics 170 
Statistical analysis was performed on SPPS V24 (IBM Deutschland GmbH, Germany) and 171 
Prism® (GraphPad Software 8.1, USA). Normally distributed data are presented as mean 172 
±standard deviation, and non-normally distributed data are presented as median (25th–75th 173 
percentile). Data are presented relative to baseline. Comparisons of normalized data between 174 
the control and MCT group were made using paired t-test for normally distributed data and 175 
Wilcoxon test for non-normally distributed data. The relationships between continuous 176 
variables were analysed using Pearson’s correlation coefficient for normally distributed data 177 




Study Population 182 
Thirty-six dogs were recruited onto this study of which twenty-nine dogs completed at least 183 
one element of the cognition assessment. The multicenter trial was carried out at five different 184 
study sites in three different countries (UK [Royal Veterinary College (RVC) (N=13, 45%) and 185 
Pride Veterinary Centre (N=4, 14%)], Germany [Tierarztpraxis Dr. A. Bathen-Nöthen (N=4, 186 
14%), University of Veterinary Medicine Hannover (N=3, 10%) and Tierarztpraxis 187 
Strassenheim (N=4, 14%)] and Finland [University of Helsinki, (N=1, 3%)]). All twenty-nine 188 
dogs had the CCDR and Trainability (C-BARQ) scored, while eighteen of those dogs 189 
underwent two cognitive tests (UK [RVC, N=13, 72%], Germany [Tierarztpraxis Strassenheim 190 
(N=4, 22%)], Finland [University of Helsinki, (N=1, 3%)]).  All 29 dogs were drug-resistant 191 
to at least one of the ASD given with less than 50% reduction in seizure frequency. Two dogs 192 
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received imepitoin only, the rest were under chronic ASD combination polytherapy (N=27). 193 
Twenty-six (89%) of the 29 dogs received phenobarbital, and the predominant combination 194 
therapy in over half of cases was phenobarbital, potassium bromide and levetiracetam (N=15). 195 
For the acute treatment of more than one seizure within 24 hours (cluster seizures) rectal 196 
diazepam (N = 29) and levetiracetam as a pulse therapy (N=3) were used by owners.  197 
 198 
Cognitive Tasks Data  199 
Sixteen purebred and two cross breed dogs were included in cognitive testing, with ten males 200 
and eight females, of which were 83% (N=15) neutered and 17% (N=3) intact. The mean age 201 
was 5.5±2.5 years and mean weight was 21.9±12.9 kilograms at the start of the trial. In over 202 
70% of dogs (N=13), a reduction in seizure frequency was observed during MCT 203 
supplementation, which was previously reported[12].  Comparing as % change relative to 204 
baseline between DS phases, dogs performed significantly better during the MCT-DS phase 205 
for both the spatial-memory task (MCT: +33.3% [+16.1 – +43.3%] v. Control: +20.8% [0 –206 
+43.2%]; P = 0.049) (Figure 1.a) or the problem-solving task (MCT: +10% [0 –  +33%] v. 207 
Control: 0% [-14.3 – +66.70 %]; P = 0.008) (Figure 1.b). Additionally, a significant, positive 208 
correlation between postprandial BHB serum concentration and improved performance in the 209 
problem-solving task was identified (p = 0.048, r = 0.45, X2 = 0.46). The higher the change in 210 
postprandial BHB serum concentration, the better the improvement seen in the problem-211 
solving task performance. 212 
 213 
CCDR and C-BARQ data 214 
The study population for which CCDR and C-BARQ data were analyzed consisted of twenty-215 
one purebred and eight cross breeds with seventeen males and twelve females, of which 79% 216 
were neutered. The mean age was 5.5±2.57 years of age and mean weight was 25.2±13.35 217 
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kilograms at the start of the trial.  218 
 219 
There was no difference in CCDR score between groups (P > 0.05). The change in C-BARQ 220 
trainability score relative to baseline was significantly improved when MCT DS was given 221 
compared to Control-DS (MCT: +20.5% [+0.5 – +49.8%]; Control: +2% [-27.5 – +30.5%] (P 222 
= 0.041) (Figure 2). When trainability score was broken down into its eight sub-components, 223 
only two of the eight measures were significantly improved in dogs under MCT-DS: Dogs 224 
consumed MCT were (i) more likely to be able to learn new tricks (P = 0.038) and (ii) faster 225 




The objective of this clinical trial was to investigate the effects of an MCT oil DS on cognition 230 
in dogs with epilepsy, who were also chronically treated with medication. Twenty-nine dogs 231 
with epilepsy completed this 6-month multi-center, randomized, controlled, cross-over 232 
prospective trial, of which eighteen underwent cognitive assessment. Both DS were added as 233 
an 9% of their metabolic energy to the base diet.  234 
 235 
Cognitive enhancing effects were observed in two cognitive tasks comparing MCT oil to 236 
control. Spatial working memory and problem-solving ability significantly differed between 237 
diets, which was confirmed in a standardised and validated questionnaire (C-BARQ), showing 238 
improved trainability scores in the MCT trial phase. Although evidence for the direct impact 239 
of CI on canine welfare is lacking, CI has the potential to alter dog-owner relationship and 240 
interactions (e.g. by cognitively impaired dogs being considered ‘naughty’ or ‘disobedient’ and 241 
thus subject to inappropriate and aversive training techniques[4]), and has a bidirectional 242 
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relationship with epilepsy[19], which compromises the quality of life for both dogs and their 243 
owners via seizures themselves, behavioural comorbidities and adverse effects of treatment 244 
[20-24]. For maintenance of a healthy and positive dog-owner relationship, including avoiding 245 
relinquishment of dogs to rescue centres, trainability plays an important role [25] and should 246 
thus be improved where possible.  247 
 248 
The overall changes reported here have been small, and are mainly due to some individual dogs 249 
having a greater improvement than others during the MCT treatment phase. Future studies need 250 
to identify the reason for the individual varied response seen here. However, in regards to 251 
canine epilepsy management, even small improvement, as here reported, in the cognitive 252 
abilities could strengthen the human animal bond. CCDR a tool developed for detecting canine 253 
dementia did not differ between diet phases. This may reflect the small sample size of this 254 
cohort leading to a lack of power to detect effects, or as has previously been discussed, it is 255 
possible that CCDR is not the ideal tool to sensitively capture epilepsy-specific cognitive 256 
impairments in dogs[17].   257 
 258 
A limitation of this study is that the changes in cognition were only assessed in ASD treated 259 
dogs.  In people, combination therapies have been shown to negatively influence cognitive 260 
functioning in a dose-dependent manner [26]. Furthermore, commonly reported side-effects of 261 
ASDs in dogs are polyphagia, lethargy and ataxia. While polyphagia might be able to influence 262 
the motivation for finding a food reward, ataxia could lead to a slower reaction time and 263 
coordination within the test room. Both may be relevant and should be also considered as 264 
limiting factors when trying to objectively study cognitive impairments in dogs with epilepsy.  265 




The higher the postprandial BHB serum concentration was the better the dogs performed in the 268 
problem-solving task. An association between BHB-levels and improvement in cognitive 269 
performance has been reported in human medicine[27], but this is a novel finding in veterinary 270 
medicine. The exact mechanism mediating ketones’ effects on cognition remains unclear, but 271 
it has been speculated that ketones can serve as a better alternative fuel source for cerebral 272 
neurons[7]. The correction of metabolic alteration, the improvement of mitochondrial function 273 
and the support of neuronal health are major targets for the use of different nutritional 274 
strategies[7]. Although glucose remains the primary energy source for the brain, ketone bodies 275 
provide an alternative, especially in the aged or diseased brain. MCTs have a high ketogenic 276 
yield and can increase ketone concentrations in the blood. Neurons use the ketone bodies as 277 
alternative energy source and compensate for the impaired glucose metabolism[27], and thus 278 
potentially improve brain function. MCTs were also found to influence neuronal signal 279 
transmission via direct receptor interaction [10]. Cognition in older dogs was positively 280 
affected, when fed with MCT-enriched diet[13], and the same diet was associated with 281 
increased BHB levels in canine epilepsy . The improved cognitive abilities reported here may 282 
be due to continuously increased BHB levels serving as alternative energy supply[27] and/or 283 
positively altered neuronal transmission via medium-chain fatty acid receptor-interactions in 284 
the brain[10].  285 
 286 
Conclusion 287 
Previous literature reported that spatial-working memory is particularly impaired  in dogs with 288 
epilepsy compared to healthy individuals [6]. This novel clinical trial provides evidence that 289 
the daily supplementation of MCTs in addition to standard ASD treatment is a promising 290 
dietary intervention to address CI in canine epilepsy. Response to MCTs was variable and it is 291 
likely that the heterogeneity of this population (e.g. age of seizure onset, seizure severity and 292 
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ASD treatment) may influence both the degree of initial cognitive impairment in this 293 
population[4, 5] and correspondingly the success of dietary interventions. Potential 294 
mechanisms of how MCT enhances cognition in dogs are proposed; however, further work is 295 
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List of abbreviations 320 
ABBREVIATIONS 
ASD Anti-seizure drug 
B Baseline 
BHB Beta-hydroxybutyrate 
CBARQ Canine Behavioral Assessment & Research Questionnaire 
CCDR Canine Cognitive Dysfunction Rating scale 
CI Cognitive impairment 
DS Dietary supplement 
IE Idiopathic epilepsy 
MCT Medium chain triacylglyceride 
RVC Royal Veterinary College 
 321 
Figure legends 322 
 323 
Figure 1.: Effects of the medium chain TAG dietary supplement (MCT, white) or control 324 
dietary supplement (control-DS, dark-grey) on (a) spatial working memory and (b) problem 325 
solving ability compared (light-pointed) (N=18). Mean scores were used to calculate the rate 326 
of change from baseline to each DS. The performance in (b) solving a problem ( P = 0 · 0078) 327 
and finding a food dropped on the floor improved significantly to baseline under MCT-intake 328 
(P = 0 · 0488). The percentage change relative to baseline scores (positive = improvement, 329 
negative = deterioration) for MCT and control-DS were compared relative to baseline. Data 330 
are shown as box-and-whisker plots (central lines of the box represent the median, lower and 331 
upper limits of the box represent the 25th and 75th percentiles and whiskers represent the 332 
minimum and maximum). Wilcoxon test were conducted to compare rate of change between 333 




Figure 2: Effects of the medium chain TAG dietary supplement (MCT, white) or control 336 
dietary supplement (control-DS, dark-grey) on trainability (N=29). Mean scores were used to 337 
calculate the rate of change from baseline to each DS. The percentage change relative to 338 
baseline scores (positive = improvement, negative = deterioration) for MCT and control-DS 339 
were compared. The overall trainability score was found significantly improved between MCT 340 
DS compared to Control-DS (MCT: +20.5% [0.5 – 49.8%]; Control: +2% [-27.5 – 30.5%], P 341 
= 0 ·  0418): (i) Dogs consumed MCT were more likely to learn new tricks (P = 0 · 03812  ) 342 
and were (ii) much faster in responding to punishment or correction (P = 0 · 0345). Data are 343 
shown as box-and-whisker plots (central lines of the box represent the median, lower and upper 344 
limits of the box represent the 25th and 75th percentiles and whiskers represent the minimum 345 
and maximum). Wilcoxon test were conducted to compare rate of change between control and 346 
MCT-DS group. * P < 0 · 05 347 
 348 
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